Daniel E E, Parrish M B, Watson E G, Fox-Threlkeld J E, Regoli D, Rainsford K D
Department of Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Am J Physiol. 1995 Jan;268(1 Pt 1):G161-70. doi: 10.1152/ajpgi.1995.268.1.G161.
This study sought to determine which tachykinin receptors were involved in contractile responses of circular muscle to tachykinins infused into isolated segments of canine ileum. Selective agonists for neurokinin receptors NK1 and NK2 as well as for substance P (SP) and neurokinin A (NKA) were infused, and selective antagonists against NK1, NK2, and NK3 receptors were tested. The responses to a submaximal concentration of NKA were reduced by a selective NK2 antagonist, SR-48968, and abolished by a combination of this antagonist with an NK1 antagonist, either CP-96,345 or RP-67580. The selective NK2 agonist, [Nle10]NKA-(4-10), had low potency. We concluded that NKA acted on typical NK2 receptors and that is action was potentiated by its additional action on NK1 receptors. Neither the contractile responses to SP nor those to [Sar9,Met(O2)11]SP given in submaximal concentrations were inhibited by CP-96,345 or RP-67580, either alone or together with SR-48968. Indeed, the two NK1-selective antagonists potentiated responses to the selective NK1 agonist, [Sar9,Met(O2)11]SP, an effect attributed to previously demonstrated prejunctional inhibitory action of the agonist. The selective NK3 agonist, succinyl-[Asp6,N-Me-Phe8]SP-(6-11), was not effective as a contractile agent, even after block of nitric oxide synthase with N omega-nitro-L-arginine. The selective NK3 antagonist, R-487, was also ineffective in blocking responses to SP. Studies with an antagonist to H1 histamine receptors suggested that contractile actions of SP did not involve histamine release from mast cells. We concluded that, in addition to typical NK1 and NK2 receptors activated by NKA and a prejunctional inhibitory receptor activated by SP and [Sar9,Met(O2)11]SP, another tachykinin receptor existed on canine ileum to initiate contractions. It is not a typical NK1, NK2, or NK3 receptor.
本研究旨在确定在犬回肠离体节段中,环形肌对注入的速激肽产生收缩反应时涉及哪些速激肽受体。分别注入了神经激肽受体NK1和NK2以及P物质(SP)和神经激肽A(NKA)的选择性激动剂,并测试了针对NK1、NK2和NK3受体的选择性拮抗剂。选择性NK2拮抗剂SR - 48968可降低对亚最大浓度NKA的反应,而该拮抗剂与NK1拮抗剂CP - 96,345或RP - 67580联合使用可消除该反应。选择性NK2激动剂[Nle10]NKA-(4 - 10)的效力较低。我们得出结论,NKA作用于典型的NK2受体,并且其作用通过对NK1受体的额外作用而增强。单独或与SR - 48968联合使用时,CP - 96,345或RP - 67580均未抑制对亚最大浓度的SP或[Sar9,Met(O2)11]SP的收缩反应。实际上,这两种NK1选择性拮抗剂增强了对选择性NK1激动剂[Sar9,Met(O2)11]SP的反应,该效应归因于先前证明的激动剂的突触前抑制作用。即使在用Nω-硝基-L-精氨酸阻断一氧化氮合酶后,选择性NK3激动剂琥珀酰-[Asp6,N-Me-Phe8]SP-(6 - 11)作为收缩剂也无效。选择性NK3拮抗剂R - 487在阻断对SP的反应方面也无效。使用H1组胺受体拮抗剂的研究表明,SP的收缩作用不涉及肥大细胞释放组胺。我们得出结论,除了由NKA激活的典型NK1和NK2受体以及由SP和[Sar9,Met(O2)11]SP激活的突触前抑制性受体外,犬回肠上还存在另一种速激肽受体以引发收缩。它不是典型的NK1、NK2或NK3受体。